Skip to main content
Frank Longo, MD, Neurology, Stanford, CA

FrankM.LongoMDPhD

Neurology Stanford, CA

Professor and Chair, Department of Neurology & Neurological Sciences, Stanford University

Dr. Longo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Longo's full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Stanford, CA 94305
    Phone+1 650-723-4000
    Fax+1 650-723-7434

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Neurology, 1984 - 1987
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Transitional Year, 1983 - 1984
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterFellowship, Neuropathology, 1981 - 1983
  • UC San Diego
    UC San DiegoPhD, Neuroscience, 1980 - 1983
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1985 - 2025
  • NC State Medical License
    NC State Medical License 2001 - 2019
  • American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Publications & Presentations

PubMed

Press Mentions

  • Small Molecule Lends Big Hope for Brutal Seizure Disorder
    Small Molecule Lends Big Hope for Brutal Seizure DisorderMarch 4th, 2022
  • Mind Jumble: Understanding Chemo Brain
    Mind Jumble: Understanding Chemo BrainMay 6th, 2020
  • Tetra Therapeutics Sees Rapid Patient Recruitment and Representative Patient Diversity in Its PICASSO Phase 2 Alzheimer’s Disease Trial
    Tetra Therapeutics Sees Rapid Patient Recruitment and Representative Patient Diversity in Its PICASSO Phase 2 Alzheimer’s Disease TrialSeptember 19th, 2019
  • Join now to see all

Grant Support

  • Stanford Neurology Resident Research TrackNational Institute Of Neurological Disorders And Stroke2010–2012
  • P75 Small Molecule Ligands For Alzheimer'S TherapyNational Institute On Aging2007–2012
  • Small Molecule Neurotrophin Mimetics To Treat Huntington'S DiseaseNational Institute Of Neurological Disorders And Stroke2010–2011
  • Novel LAR Isoforms: A New Class Of Neurotrophic AgentsNational Institute On Aging2002–2003
  • Novel LAR Isoforms--A New Class Of Neurotrophic AgentsNational Institute On Aging2001
  • Novel LAR Isoforms--A New Class Of Neurotrophic AgentsNational Institute On Aging2000
  • Novel LAR Isoforms--A New Class Of Neutrophic AgentsNational Institute On Aging1995–1997
  • Aging &Neuronal Death--First Generation Of NGF AnalogNational Institute On Aging1991–1993
  • Brain Injury &Transplants: Role Of Nerve Growth FactorNational Institute Of Neurological Disorders And Stroke1987–1988